About: Pharmacological Properties of N-(3,5-Diamino-6-chloropyrazine-2-carbonyl)-N'-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine Methanesulfonate (552-02), a Novel Epithelial Sodium Channel Blocker with Potential Clinical Efficacy for Cystic Fibrosis L

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Pharmacological Properties of N-(3,5-Diamino-6-chloropyrazine-2-carbonyl)-N'-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine Methanesulfonate (552-02), a Novel Epithelial Sodium Channel Blocker with Potential Clinical Efficacy for Cystic Fibrosis L Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scholarly article by A. J. Hirsh et al published 17 January 2008 in Journal of Pharmacology and Experimental Therapeutics

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) article scientifique publié en 2008 (fr) наукова стаття, опублікована в січні 2008 (uk) im Januar 2008 veröffentlichter wissenschaftlicher Artikel (de) scholarly article by A. J. Hirsh et al published 17 January 2008 in Journal of Pharmacology and Experimental Therapeutics (en)
publication date	wds:Q56457085-A410D5BB-3E47-4C87-999B-73804F1A014F
publication date	2008-01-17 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q56457085-2519B431-0C3A-43AD-81DA-ADA52C974910
language of work or name	English
author name string	wds:Q56457085-065A89C3-0098-48E2-8366-1DA6FCD25530 wds:Q56457085-10BB91EE-BFA1-49C4-A5F3-055CD285AD0F wds:Q56457085-2A6A221B-6081-4641-A211-44839AD3DB4E wds:Q56457085-2DB498BD-8CAE-461A-8E75-A74FE21A9D6A wds:Q56457085-303C6078-AE8F-4EAB-957A-7E211234F370 wds:Q56457085-3BC3BFC1-16C6-4AEE-9EAA-D3FCF0521ECA wds:Q56457085-52127E21-7940-4E49-BF00-41871EDF9D5F wds:Q56457085-56A66D9A-033B-43A5-8030-1699587E936B wds:Q56457085-6AB7FE3C-D60A-4F56-974A-F46CC5695C6A wds:Q56457085-6FC62659-A8B0-4227-B2F4-FD189FA7FB42 wds:Q56457085-84357489-23E1-4C94-BBE3-C6E9C31D92B2 wds:Q56457085-856C9B6A-F7E2-4A31-AD03-C23785A9FCBD wds:Q56457085-ED645600-5876-4C4B-A899-06D7A4C50C97 wds:Q56457085-F2725908-81CB-4C90-8E0B-C2827F088E89
author name string	J. Zhang M. R. Johnson K. B. Johnson M. Donowitz W. M. Abraham R. C. Boucher R. A. Caldwell A. J. Hirsh A. Zamurs B. Cha J. A. St. George J. Fleegle J. R. Sabater W. R. Thelin
rdfs:label	Pharmacological Properties of N-(3,5-Diamino-6-chloropyrazine-2-carbonyl)-N'-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine Methanesulfonate (552-02), a Novel Epithelial Sodium Channel Blocker with Potential Clinical Efficacy for Cystic Fibrosis L (en) Pharmacological Properties of N-(3,5-Diamino-6-chloropyrazine-2-carbonyl)-N'-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine Methanesulfonate (552-02), a Novel Epithelial Sodium Channel Blocker with Potential Clinical Efficacy for Cystic Fibrosis L (nl)
skos:prefLabel	Pharmacological Properties of N-(3,5-Diamino-6-chloropyrazine-2-carbonyl)-N'-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine Methanesulfonate (552-02), a Novel Epithelial Sodium Channel Blocker with Potential Clinical Efficacy for Cystic Fibrosis L (en) Pharmacological Properties of N-(3,5-Diamino-6-chloropyrazine-2-carbonyl)-N'-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine Methanesulfonate (552-02), a Novel Epithelial Sodium Channel Blocker with Potential Clinical Efficacy for Cystic Fibrosis L (nl)
name	Pharmacological Properties of N-(3,5-Diamino-6-chloropyrazine-2-carbonyl)-N'-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine Methanesulfonate (552-02), a Novel Epithelial Sodium Channel Blocker with Potential Clinical Efficacy for Cystic Fibrosis L (en) Pharmacological Properties of N-(3,5-Diamino-6-chloropyrazine-2-carbonyl)-N'-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine Methanesulfonate (552-02), a Novel Epithelial Sodium Channel Blocker with Potential Clinical Efficacy for Cystic Fibrosis L (nl)
title	wds:Q56457085-6232852A-908A-42CB-AD50-EF123DF4542E
title	Pharmacological Properties of N-(3,5-Diamino-6-chloropyrazine-2-carbonyl)-N'-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine Methanesulfonate (552-02), a Novel Epithelial Sodium Channel Blocker with Potential Clinical Efficacy for Cystic Fibrosis L (en)
page(s)	wds:Q56457085-283528C6-621B-4E3F-90F5-1B87DF81B0D8
page(s)	77-88
instance of	wds:Q56457085-32E1E916-CF10-4C22-B46E-FEC3F393B39C
instance of	scholarly article
main subject	wds:Q56457085-7D35FC4F-2A9F-40DF-AB86-E590D06C39F0 wds:Q56457085-D1F35BBC-CAC7-429E-AD0C-41F230EAE701
main subject	cystic fibrosis pharmacology
PubMed ID	wds:Q56457085-9FDB7948-64C2-4F6E-A14C-24AAFF97FDB7
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/18218832
PubMed ID	18218832
published in	wds:Q56457085-71C3E08C-5333-48A3-BDC2-D1F97214FA06
published in	Journal of Pharmacology and Experimental Therapeutics
issue	wds:Q56457085-28BD9062-AA38-41F9-8459-2AFCFBF5A081
volume	wds:Q56457085-A1C16CA6-EC14-449A-94F3-5DF73CE940A2
issue	1
volume	325
DOI	wds:Q56457085-23D61E41-2D7D-4351-9135-F20192338220
DOI	http://dx.doi.org/10.1124/JPET.107.130443
DOI	10.1124/JPET.107.130443
ResearchGate publication ID	wds:Q56457085-F1BE04E8-DCCB-47D4-9C2E-A7E8F89B4D8D
ResearchGate publication ID	5632596
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q56457085
is cites work of	Early pulmonary inflammation and lung damage in children with cystic fibrosis Regulation of the epithelial Na+ channel and airway surface liquid volume by serine proteases New pulmonary therapies directed at targets other than CFTR. Role of the amiloride-sensitive epithelial Na+ channel in the pathogenesis and as a therapeutic target for cystic fibrosis lung disease New horizons in the treatment of cystic fibrosis Linking increased airway hydration, ciliary beating, and mucociliary clearance through ENaC inhibition Novel agents in cystic fibrosis NVP-QBE170: an inhaled blocker of the epithelial sodium channel with a reduced potential to induce hyperkalaemia The ENaC-overexpressing mouse as a model of cystic fibrosis lung disease The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles. Strategies in early clinical development for the treatment of basic defects of cystic fibrosis. Non-invasive airway health assessment: synchrotron imaging reveals effects of rehydrating treatments on mucociliary transit in-vivo Pharmacological therapy for cystic fibrosis: from bench to bedside Preventive but not late amiloride therapy reduces morbidity and mortality of lung disease in betaENaC-overexpressing mice. Reduced sodium transport with nasal administration of the prostasin inhibitor camostat in subjects with cystic fibrosis ENaCs and ASICs as therapeutic targets Measurement of the airway surface liquid volume with simple light refraction microscopy Cystic fibrosis transmembrane conductance regulator modulators for personalized drug treatment of cystic fibrosis: progress to date. The guinea-pig tracheal potential difference as an in vivo model for the study of epithelial sodium channel function in the airways Front-runners for pharmacotherapeutic correction of the airway ion transport defect in cystic fibrosis Amiloride docking to acid-sensing ion channel-1 Airway drug pharmacokinetics via analysis of exhaled breath condensate Managing the underlying cause of cystic fibrosis: a future role for potentiators and correctors Duration of action of hypertonic saline on mucociliary clearance in the normal lung ENaC inhibitors for the treatment of cystic fibrosis Epithelial sodium channel silencing as a strategy to correct the airway surface fluid deficit in cystic fibrosis The function and regulation of acid-sensing ion channels (ASICs) and the epithelial Na(+) channel (ENaC): IUPHAR Review 19. Reduced NHE3-mediated Na+ absorption increases survival and decreases the incidence of intestinal obstructions in cystic fibrosis mice Potential Role of Antihypertensive Medications in Preventing Excessive Arterial Stiffening Influenza virus infection alters ion channel function of Airway and alveolar cells: Mechanisms and physiological sequelae Losartan Rescues Inflammation-related Mucociliary Dysfunction in Relevant Models of Cystic Fibrosis

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 183 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software